What did the FDA approve leucovorin for?

FDA clears leucovorin for a specific genetic disorder

The agency approved leucovorin, a synthetic form of vitamin B9, for a rare condition known as cerebral folate deficiency. That disorder is caused by problems in the body’s ability to transport or use folate in the brain; it can produce neurological symptoms that sometimes overlap with features seen in autism spectrum disorders. The approval recognizes evidence that targeted folate replacement benefits the metabolic defect underlying the rare diagnosis.

The decision does not extend to autism more broadly. Previous public statements and political promotion of the drug had suggested it as an autism treatment, but the clinical data do not support that use. The Food and Drug Administration clarified that the new indication is limited to patients with confirmed cerebral folate deficiency and that there is insufficient evidence to endorse leucovorin as a therapy for autism spectrum disorder in the general population.

Why this matters

• For families of children with cerebral folate deficiency, the approval formalizes access to an indicated treatment and can make insurance coverage and clinical guidance clearer.
• For clinicians, it narrows appropriate prescribing: testing for the specific metabolic defect is the rational pathway before treatment.
• For the broader autism community, the move underscores that a single drug approval for a rare metabolically defined disorder is not the same as an endorsement of that drug for autism in general.

Looking ahead, researchers and clinicians will need to: 1) ensure accurate diagnosis of cerebral folate deficiency before prescribing, 2) educate families about what the approval does—and does not—mean, and 3) continue rigorous studies into interventions for autism spectrum conditions rather than relying on extrapolation from a rare, mechanistically distinct disorder.